Efalizumab Therapy for Psoriasis in Patients with Inadequate Responses to Etanercept

ISSN： 1175-0561

Source： American Journal of Clinical Dermatology, Vol.10, Iss.2, 2009-01, pp. : 134-140

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis

By Weinberg J.M.

Clinical Therapeutics, Vol. 25, Iss. 10, 2003-10 ,pp. : 2487-2505

Elsevier

Access to resources Recommend Favorite

Prevalence of Joint Disease in Patients with Psoriasis: Implications for Therapy

By Zachariae H.

American Journal of Clinical Dermatology, Vol. 4, Iss. 7, 2003-01 ,pp. : 441-447

Adis International

Access to resources Recommend Favorite

Spotlight on Etanercept in Plaque Psoriasis and Psoriatic Arthritis

By Goldsmith David R. Wagstaff Antona J.

BioDrugs, Vol. 19, Iss. 6, 2005-01 ,pp. : 401-403

Adis International

Access to resources Recommend Favorite

Efalizumab

By Wellington Keri Perry Caroline M.

American Journal of Clinical Dermatology, Vol. 6, Iss. 2, 2005-01 ,pp. : 113-118

Adis International

Access to resources Recommend Favorite

Efalizumab: A Review of its Use in the Management of Chronic Moderate-to-Severe Plaque Psoriasis

By Frampton James E. Plosker Greg L.

American Journal of Clinical Dermatology, Vol. 10, Iss. 1, 2009-01 ,pp. : 51-72

Adis International

Access to resources Recommend Favorite